Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC
Primary angiitis of the central nervous system (PACNS) is a rare condition that causes blood vessels in the brain and spinal cord to become inflamed. Once doctors bring the swelling under control, long-term "maintenance" treatment is needed to keep the condition from flaring up again. This Phase II clinical trial compares two different maintenance medicines to see which is more effective. Participants are randomly assigned to receive either azathioprine, which is taken as a daily tablet, or rituximab, which is given directly into a vein through a drip at planned hospital visits. The trial follows patients for two years. Researchers will track how long participants stay free from symptoms, check brain MRI scans for any new blood vessel changes, monitor steroid use, and measure quality of life. The aim is to help doctors find the safest, most effective way to protect brain health in people with this condition.
At a glance
What is this study about?
Primary angiitis of the central nervous system is a rare but serious condition. The body's immune system mistakenly attacks healthy blood vessels in the brain and spinal cord, causing them to swell and narrow. This can limit blood supply and cause headaches, confusion, or even strokes. Treatment usually starts with strong medicines to quickly calm the inflammation. Once the condition is quiet, patients start maintenance therapy to stop it from returning.
Currently, many doctors prescribe daily tablets called azathioprine to keep the illness in check. However, another medicine called rituximab might work even better. Rituximab targets specific cells in the immune system and is given through a drip into a vein during scheduled hospital appointments. Researchers want to find out whether rituximab does a better job of preventing flare-ups than daily azathioprine tablets.
The study follows participants closely over a two-year period. By looking at regular brain scans and checking for any returning symptoms, the research team will see which medicine keeps patients well for longer. They will also look at whether rituximab allows people to lower their doses of steroid medicines, which can cause unpleasant side effects when used long term.
Understanding which medicine is superior could change the standard of care for people diagnosed with this rare condition across the UK and beyond. It gives patients and doctors clearer guidance on how to prevent flare-ups and protect long-term brain health.
Key takeaways
- Compares two medicines (daily tablets vs a hospital drip) to prevent brain vessel inflammation from returning.
- Open to adults aged 18 and older whose condition is currently stable.
- Follows participants closely over a two-year period.
- Involves regular check-ups, blood tests, and MRI brain scans.
- Taking part is completely voluntary and you can leave at any time.
Who may be eligible?
This trial is designed for adults aged 18 and over who have been diagnosed with primary angiitis of the central nervous system. Participants must be at the stage where their initial inflammation is under control and they are ready to begin long-term maintenance treatment to stay well.
Both men and women can take part. Because this condition is uncommon and shares symptoms with other illnesses, doctors will carefully review your medical history, test results, and brain scans to ensure this trial is suitable for you.
You may not be eligible if you have an active severe infection, another major brain disorder, or health issues that make these immune-modifying treatments unsafe. Your hospital doctor will explain all safety requirements before you decide to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with primary angiitis of the central nervous system.
- My condition is currently stable and ready for maintenance treatment.
- I am able to attend regular hospital appointments and have MRI scans.
- I am willing to take daily tablets or receive treatments through a drip.
What does participation involve?
If you take part, your involvement will last for around two years (24 months). A computer will randomly assign you to one of two groups. One group takes azathioprine tablets each day at home. The other group receives rituximab as a slow drip into a vein during hospital day-visits.
Throughout the study, you will have regular clinic visits so the team can monitor your health. These visits will include physical and neurological checks, blood tests, and MRI brain scans to look for any hidden vessel inflammation. You will also answer short questionnaires about your daily wellbeing and keep track of any other medicines you take.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What does a randomised trial mean?
It means a computer puts you into a treatment group by chance, like flipping a coin. This makes sure the two groups can be compared fairly.
Will I know which medicine I am receiving?
Yes. This is an 'open-label' study, so both you and your doctor will know whether you are taking the daily tablets or receiving the infusions.
How often will I need to visit the hospital?
You will need to attend regular clinic check-ups and MRI scans over the two years. If you are in the rituximab group, you will also attend hospital for your infusions.
What happens if my symptoms return during the trial?
Your safety is always the priority. If your symptoms flare up or your scans show new inflammation, your medical team will step in and adjust your treatment immediately.
Can I continue taking other medicines?
Yes, in most cases. Your trial doctor will check all your regular medicines, including any steroids, to make sure they are safe to use during the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.